Celldex Therapeutics Inc [CLDX] stock prices are up 3.52% to $26.14 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CLDX shares have gain 6.22% over the last week, with a monthly amount glided 15.66%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on April 28, 2025, when Canaccord Genuity initiated its Buy rating and assigned the stock a price target of $64. Previously, Morgan Stanley started tracking the stock with Overweight rating on March 20, 2025, and set its price target to $46. On February 13, 2025, UBS initiated with a Buy rating and assigned a price target of $44 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $70 on October 07, 2024. Goldman initiated its recommendation with a Neutral and recommended $45 as its price target on September 30, 2024. Wolfe Research downgraded its rating to Peer Perform for this stock on September 27, 2024. In a note dated June 18, 2024, Stifel initiated an Buy rating and provided a target price of $58 on this stock.
The stock price of Celldex Therapeutics Inc [CLDX] has been fluctuating between $14.40 and $36.76 over the past year. Currently, Wall Street analysts expect the stock to reach $58.2 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $26.14 at the most recent close of the market. An investor can expect a potential return of 122.65% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
The Celldex Therapeutics Inc [NASDAQ:CLDX] reported sales of 5.79M for trailing twelve months, representing a drop of -70.78%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -40.54%, Pretax Profit Margin comes in at -34.47%, and Net Profit Margin reading is -34.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.28 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.46 points at the first support level, and at 24.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.59, and for the 2nd resistance point, it is at 27.05.
Ratios To Look Out For
It’s worth pointing out that Celldex Therapeutics Inc [NASDAQ:CLDX]’s Current Ratio is 19.67. On the other hand, the Quick Ratio is 19.67, and the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 299.80, the price to book ratio is 2.65.
Transactions by insiders
Recent insider trading involved Jimenez Freddy A., SVP & GENERAL COUNSEL, that happened on Aug 13 ’25 when 771.0 shares were sold. PRESIDENT & CEO, Marucci Anthony S completed a deal on Nov 11 ’24 to buy 11500.0 shares.
